Laura Brandolini

R&d
L'aquila, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat (Diabetes Metab J 2025;49:990-1005).

Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat (Diabetes Metab J 2025;49:990-1005).

Journal: Diabetes & metabolism journal

Published: May 13, 2026

Refining free fatty acid receptor agonism for metabolic control: Pharmacological and functional features of novel dual GPR40/GPR120 ligands.

Refining free fatty acid receptor agonism for metabolic control: Pharmacological and functional features of novel dual GPR40/GPR120 ligands.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 15, 2026

Presynaptic release-regulating C5a receptors in the spinal cord of healthy mice and of animals suffering from experimental autoimmune encephalomyelitis: impact of the C5aR antagonist DF2593A.

Presynaptic release-regulating C5a receptors in the spinal cord of healthy mice and of animals suffering from experimental autoimmune encephalomyelitis: impact of the C5aR antagonist DF2593A.

Journal: Neuropharmacology

Published: December 22, 2025

CXCR2 antagonism as a promising therapeutic approach for pulmonary fibrosis therapy.

CXCR2 antagonism as a promising therapeutic approach for pulmonary fibrosis therapy.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 17, 2025

Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat (Diabetes Metab J 2025;49:990-1005).

Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat (Diabetes Metab J 2025;49:990-1005).

Journal: Diabetes & metabolism journal

Published: November 17, 2025

Evaluation of the gastrotolerability of ketoprofen, lysine, and gabapentin co-crystal administration in an in vitro model of gastric epithelium: a proteomic update.

Evaluation of the gastrotolerability of ketoprofen, lysine, and gabapentin co-crystal administration in an in vitro model of gastric epithelium: a proteomic update.

Journal: PloS one

Published: March 06, 2025

A novel free fatty acid receptor agonist improving metabolic health in Drosophila models.

A novel free fatty acid receptor agonist improving metabolic health in Drosophila models.

Journal: Pharmacological research

Published: February 26, 2025

Beyond inflammation: the multifaceted therapeutic potential of targeting the CXCL8-CXCR1/2 axis in type 1 diabetes.

Beyond inflammation: the multifaceted therapeutic potential of targeting the CXCL8-CXCR1/2 axis in type 1 diabetes.

Journal: Frontiers in immunology

Published: February 13, 2025

Reparixin as a Potential Antiepileptogenic Agent: Modulation of the CXCL1-CXCR1/2 Axis and Seizure Activity in a Kindling Rat Model of Temporal Lobe Epilepsy.

Reparixin as a Potential Antiepileptogenic Agent: Modulation of the CXCL1-CXCR1/2 Axis and Seizure Activity in a Kindling Rat Model of Temporal Lobe Epilepsy.

Journal: International journal of molecular sciences

Published: February 06, 2025

Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat.

Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat.

Journal: Diabetes & metabolism journal

Published: August 25, 2024

TNFα-CXCR1/2 partners in crime in insulin resistance conditions.

TNFα-CXCR1/2 partners in crime in insulin resistance conditions.

Journal: Cell death discovery

Published: July 04, 2024

Early transtympanic administration of rhBDNF exerts a multifaceted neuroprotective effect against cisplatin-induced hearing loss.

Early transtympanic administration of rhBDNF exerts a multifaceted neuroprotective effect against cisplatin-induced hearing loss.

Journal: British journal of pharmacology

Published: April 30, 2024

Showing 1-12 of 55

Last Updated: 09/26/2026